Patrick Soon-Shiong, M.D., FRCS (C), FACS
Not independent
Tenure on this board
New nominee
Meeting calendar
IBRX · Annual meeting · Tuesday, June 9, 2026
Immunitybio Inc
9 nominees · 2 ballot items.
Election of nine directors to serve until the 2027 annual meeting and ratification of Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026.
Market cap
$7.8B
1Y TSR
+194.7%
Board grade
C-
Record date
Apr 13, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026
Follow how the vote landed and what changed on Immunitybio Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect nine directors from the nominated current directors to serve one-year terms expiring at the 2027 annual meeting.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the selection of Deloitte & Touche LLP as ImmunityBio’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
7.1 yrs
Also a director at
Celldex Therapeutics Inc (CLDX)
Not independent
Tenure on this board
5.3 yrs
Independent
Tenure on this board
11.1 yrs
Independent
Tenure on this board
5.4 yrs
Linda Maxwell, M.D., M.B.A., FRCSC
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
5.4 yrs
Not independent
Tenure on this board
19.5 yrs
Independent
Tenure on this board
0.6 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | STATE STREET CORP | 1.7% | 17,708,103 | $136M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6% | 16,322,844 | $125M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.4% | 15,127,714 | $116M |
| 4 | BlackRock, Inc. | 1.3% | 13,601,860 | $104M |
| 5 | D. E. Shaw Co., Inc.Activist | 1.2% | 12,571,597 | $96M |
| 6 | BlackRock, Inc. | 0.8% | 8,870,367 | $68M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.7% | 6,975,488 | $54M |
| 8 | TWO SIGMA INVESTMENTS, LP | 0.4% | 4,385,500 | $34M |
| 9 | HRT FINANCIAL LP | 0.4% | 3,925,446 | $30M |
| 10 | Woodline Partners LP | 0.3% | 3,447,346 | $26M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Immunitybio Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Immunitybio Inc 2026 annual meeting?
- Immunitybio Inc (IBRX) holds its 2026 annual shareholder meeting on Tuesday, June 9, 2026.
- What is the record date for the Immunitybio Inc 2026 meeting?
- The record date for the Immunitybio Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Immunitybio Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Immunitybio Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Immunitybio Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Immunitybio Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.